Literature DB >> 22414885

Pros and cons of patent ductus arteriosus ligation: hemodynamic changes and other morbidities after patent ductus arteriosus ligation.

Shahab Noori1.   

Abstract

Although surgical ligation of a persistent patent ductus arteriosus resolves the adverse hemodynamic consequences of the systemic-to-pulmonary shunt and may confer some long-term benefits, it is also associated with both immediate and long-term negative effects. The population that benefits from or is harmed by the procedure is not clearly defined. Although indiscriminate ligation of the patent ductus arteriosus in all patients is not supported by the available information, the recent suggestion declaring the ductus harmless is not supported either. As we await the results of appropriately designed randomized control studies to define the indications for ligation, we must use clinical and echocardiographic indicators of a hemodynamically significant ductus arteriosus and thoughtful assessment of each individual patient to help guide us in addressing this complex problem. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22414885     DOI: 10.1053/j.semperi.2011.09.024

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  11 in total

1.  The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment.

Authors:  Jeff Reese; Matthew M Laughon
Journal:  J Pediatr       Date:  2015-08-24       Impact factor: 4.406

2.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

3.  Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone.

Authors:  Elaine L Shelton; Gerren Ector; Cristi L Galindo; Christopher W Hooper; Naoko Brown; Irene Wilkerson; Elise R Pfaltzgraff; Bibhash C Paria; Robert B Cotton; Jason Z Stoller; Jeff Reese
Journal:  Physiol Genomics       Date:  2014-05-01       Impact factor: 3.107

Review 4.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

Review 5.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

6.  Surgical Ligation Versus Percutaneous Closure of Patent Ductus Arteriosus in Very Low-Weight Preterm Infants: Which are the Real Benefits of the Percutaneous Approach?

Authors:  A Rodríguez Ogando; I Planelles Asensio; A Rodríguez Sánchez de la Blanca; F Ballesteros Tejerizo; M Sánchez Luna; J M Gil Jaurena; C Medrano López; J L Zunzunegui Martínez
Journal:  Pediatr Cardiol       Date:  2017-11-08       Impact factor: 1.655

Review 7.  Patent ductus arteriosus in preterm infants: is early transcatheter closure a paradigm shift?

Authors:  P Vali; S Lakshminrusimha; A Pelech; M Underwood; F Ing
Journal:  J Perinatol       Date:  2019-09-27       Impact factor: 3.225

8.  Ibuprofen Versus Indomethacin for Medical Closure of the Patent Arterial Duct: A Pooled Analysis by Route of Administration.

Authors:  Rohit Loomba; Karan Nijhawan
Journal:  Cureus       Date:  2015-06-04

9.  Speckle-Tracking Echocardiography in Dogs With Patent Ductus Arteriosus: Effect of Percutaneous Closure on Cardiac Mechanics.

Authors:  I Spalla; C Locatelli; A M Zanaboni; P Brambilla; C Bussadori
Journal:  J Vet Intern Med       Date:  2016-05       Impact factor: 3.333

10.  Evaluation of left ventricular dimension and systolic function by standard transthoracic echocardiography before and 24-hours after percutaneous closure of patent ductus arteriosus in 120 dogs.

Authors:  Diego Piantedosi; Alfonso Piscitelli; Angela De Rosa; Blanca Serrano Lopez; Marta Claretti; Elisabetta Boz; Laura Mazzoni; Iolanda Navalon Calvo; Paolo Ciaramella; Claudio Bussadori
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.